JP2005527502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527502A5 JP2005527502A5 JP2003569646A JP2003569646A JP2005527502A5 JP 2005527502 A5 JP2005527502 A5 JP 2005527502A5 JP 2003569646 A JP2003569646 A JP 2003569646A JP 2003569646 A JP2003569646 A JP 2003569646A JP 2005527502 A5 JP2005527502 A5 JP 2005527502A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- tetrahydrofuran
- diol
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- -1 3-tetrahydrofuranyl Chemical group 0.000 claims 18
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- SSYDTHANSGMJTP-UHFFFAOYSA-N oxolane-3,4-diol Chemical compound OC1COCC1O SSYDTHANSGMJTP-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35796102P | 2002-02-19 | 2002-02-19 | |
| PCT/US2003/007289 WO2003070739A1 (en) | 2002-02-19 | 2003-02-19 | Partial and full agonists of a1 adenosine receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527502A JP2005527502A (ja) | 2005-09-15 |
| JP2005527502A5 true JP2005527502A5 (enExample) | 2006-01-05 |
Family
ID=27757687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569646A Pending JP2005527502A (ja) | 2002-02-19 | 2003-02-19 | Ａ１アデノシン受容体の部分的および全アゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7144871B2 (enExample) |
| EP (2) | EP1476455A1 (enExample) |
| JP (1) | JP2005527502A (enExample) |
| KR (2) | KR20040084929A (enExample) |
| CN (2) | CN1636009A (enExample) |
| AU (2) | AU2003223237C1 (enExample) |
| CA (1) | CA2476683C (enExample) |
| IL (2) | IL163613A0 (enExample) |
| MX (1) | MXPA04008008A (enExample) |
| NO (1) | NO330243B1 (enExample) |
| NZ (1) | NZ534801A (enExample) |
| PL (1) | PL372145A1 (enExample) |
| RU (1) | RU2317994C2 (enExample) |
| WO (1) | WO2003070739A1 (enExample) |
| ZA (1) | ZA200406607B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713946B2 (en) * | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| PL372145A1 (en) * | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
| DE102004032651A1 (de) * | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
| CA2573682A1 (en) * | 2004-07-12 | 2006-02-16 | Cv Therapeutics, Inc. | Process for the preparation of a1 adenosine receptor agonists |
| RU2443708C2 (ru) * | 2007-05-17 | 2012-02-27 | Си Ви Терапьютикс, Инк. | Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций |
| WO2012012736A2 (en) * | 2010-07-23 | 2012-01-26 | The Ohio State University | Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway |
| JP2015172077A (ja) * | 2015-06-24 | 2015-10-01 | 中国医学科学院葯物研究所 | Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途 |
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| TN2018000310A1 (en) | 2016-03-10 | 2020-01-16 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
| CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| JP7101171B2 (ja) | 2016-10-03 | 2022-07-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 |
| MX391405B (es) | 2016-12-15 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-mll. |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| ES2971035T3 (es) | 2017-02-27 | 2024-06-03 | Janssen Pharmaceutica Nv | Uso de biomarcadores en la identificación de pacientes con cáncer que mostrarán respuesta al tratamiento con un inhibidor de prmt5 |
| CA3084449A1 (en) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
| US10421734B1 (en) * | 2018-08-31 | 2019-09-24 | Sami Labs Limited | Process for the preparation of enantiopure 3-amino tetrahydrofuran and its salts |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| PH12021553075A1 (en) | 2019-06-12 | 2023-09-11 | Janssen Pharmaceutica Nv | Novel spirobicyclic intermediates |
| AU2020404305A1 (en) | 2019-12-19 | 2022-08-04 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6576619B2 (en) * | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
| WO2001040799A2 (en) * | 1999-12-03 | 2001-06-07 | Cv Therapeutics, Inc. | Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| PL372145A1 (en) * | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
-
2003
- 2003-02-19 PL PL03372145A patent/PL372145A1/xx not_active Application Discontinuation
- 2003-02-19 CN CNA038041936A patent/CN1636009A/zh active Pending
- 2003-02-19 AU AU2003223237A patent/AU2003223237C1/en not_active Ceased
- 2003-02-19 WO PCT/US2003/007289 patent/WO2003070739A1/en not_active Ceased
- 2003-02-19 CA CA2476683A patent/CA2476683C/en not_active Expired - Fee Related
- 2003-02-19 CN CNA2008102118341A patent/CN101392012A/zh active Pending
- 2003-02-19 EP EP03719367A patent/EP1476455A1/en not_active Withdrawn
- 2003-02-19 NZ NZ534801A patent/NZ534801A/en not_active IP Right Cessation
- 2003-02-19 MX MXPA04008008A patent/MXPA04008008A/es active IP Right Grant
- 2003-02-19 KR KR10-2004-7012954A patent/KR20040084929A/ko not_active Ceased
- 2003-02-19 EP EP10013734A patent/EP2412716A1/en not_active Withdrawn
- 2003-02-19 US US10/370,679 patent/US7144871B2/en not_active Expired - Fee Related
- 2003-02-19 RU RU2004125492/04A patent/RU2317994C2/ru not_active IP Right Cessation
- 2003-02-19 KR KR1020107006113A patent/KR101032005B1/ko not_active Expired - Fee Related
- 2003-02-19 JP JP2003569646A patent/JP2005527502A/ja active Pending
- 2003-02-19 IL IL16361303A patent/IL163613A0/xx unknown
-
2004
- 2004-08-19 ZA ZA200406607A patent/ZA200406607B/en unknown
- 2004-08-19 IL IL163613A patent/IL163613A/en not_active IP Right Cessation
- 2004-09-17 NO NO20043907A patent/NO330243B1/no not_active IP Right Cessation
-
2006
- 2006-08-24 US US11/510,550 patent/US7696181B2/en not_active Expired - Fee Related
-
2008
- 2008-11-21 AU AU2008249143A patent/AU2008249143B2/en not_active Ceased
-
2009
- 2009-07-23 US US12/508,385 patent/US20090325896A1/en not_active Abandoned